Breaking News

Upgraded Syngene Biologics Facility to Be Operational in Second Half of 2024

New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day.

Author Image

By: Charlie Sternberg

Associate Editor

Syngene International, a global contract research, development and manufacturing organization (CRDMO), has announced that its newly upgraded biologics facility (Unit 3) in India will be operational for clinical and commercial supply in the second half of 2024.   The facility will be available for biotech and pharma customers seeking drug substance and drug product contract manufacturing. It includes two production suites with five 2KL single use bioreactors each, for a total capacity of 20KL. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters